NCT06516445

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

A Clinical Study of Short Course Radiotherapy (SCRT) Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
RADIATION	SCRT	5×5Gy，5Gy/d，QD，D1-D5
DRUG	Camrelizumab	200mg, D1, ivgtt, Q3W, C1-4
DRUG	Fluzoparib	100mg, BID, PO, Q3W, C1-4
DRUG	CAPEOX	Capecitabine: 1000 mg/m2, BID, PO，D1-14, Q3W, C1-C4； Oxaliplatin: 130mg/m2, D1, ivgtt, 0-2h，Q3W，C1-4

Timeline

• Start date: 2023-06-28
• Primary completion: 2025-06-28
• Completion: 2026-06-28
• First posted: 2024-07-24
• Last updated: 2024-07-24

Locations

1 site across 1 country: China